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Anal cancer is common in people living with HIV (PLWH); men who have sex with men 
(MSM)1, and heterosexuals with multicentric human papillomavirus infection. The efficacy 
of screening for anal cancer is unknown. 
 
We conducted web-based serial cross-sectional surveys in 20122 and 2018 to examine 
changes in anal cancer screening awareness, attitudes and practices amongst sexual health 
clinicians in the UK. 72 (62.1%) of 116 sexual health clinics approached responded in 2012, 
all were senior clinicians, and 73 (17.8%) of 411 clinics responded in 2018, from a variety of 
healthcare professionals (66 surveys from unique clinics were analysed in 2018).  
 
We observed poorer knowledge of screening methods in 2018, even after excluding 
responses from General Practitioners with an interest in sexual health and other non-
specialist settings; >90% of responders were aware of cytology, digital ano-rectal 
examination (DARE), or high-resolution anoscopy (HRA) in 2012, dropping to <40% for each 
in 2018. Practices remained similar for those that screened PLWH regularly. Most enquired 
about symptoms associated with anal cancer. Routine DARE was rare (three (4.2%) in 2012, 
one (1.5%) in 2018) .  
 
Clinics regularly screening high risk groups (PLWH MSM) increased (four clinics (5.6%) in 
2012, seven clinics (10.6%) in 2018. Patients with confirmed anal intraepithelial neoplasia 
(AIN) were managed according to local service availability. A greater proportion of clinics 
referred cases of AIN for HRA in 2018 (14 (21.2%) compared to 10 (13.9%) in 2012). 
Screening in high risk groups continued to be perceived as useful (48 (69.6%) in 2012, 53 
(80.3%) in 2018). 
 
To our knowledge, this is the only national, serial cross-sectional survey of anal cancer 
screening attitudes and practices in the UK. Since 2012, commissioning for different sexual 
health services in England has changed. Our results highlight a reduction in knowledge of 
anal cancer screening methods among sexual health clinicians between 2012 and 2018.  
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